Demonstrating the value of RWEA new cross-industry effort hopes to research the benefits of RWE and promote acceptance of alternatives to traditional Share XDemonstrating the value of RWEhttps://pharmaphorum.com/views-analysis-oncology/demonstrating-the-value-of-rwe/
Searching for new hope in Alzheimer’sFor the best part of two decades, it seemed as if pharma hit a brick wall as it Share XSearching for new hope in Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/searching-for-new-hope-in-alzheimers/
Q&A: Albireo’s Ron Cooper on bile acid modulationWhile bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies Share XQ&A: Albireo’s Ron Cooper on bile acid modulationhttps://pharmaphorum.com/r-d/views-analysis-r-d/qa-albireos-ron-cooper-on-bile-acid-modulation/
Q&A: Sangamo’s Duncan McKay on genomic medicinesWe talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future Share XQ&A: Sangamo’s Duncan McKay on genomic medicineshttps://pharmaphorum.com/views-analysis-market-access/qa-sangamos-duncan-mckay-on-genomic-medicines/
Q&A: Adaptimmune’s Elliot Norry on cell therapyDr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing Share XQ&A: Adaptimmune’s Elliot Norry on cell therapyhttps://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/
Bridging the gap between industry and charities: Enabling PPI in researchPublic and patient involvement (PPI) in clinical research is the new normal, but bridging the gap between how Share XBridging the gap between industry and charities: Enabling PPI in researchhttps://pharmaphorum.com/views-analysis-patients/bridging-the-gap-between-industry-and-charities-enabling-ppi-in-research/
A new breed of pharma manufacturingOver the last few years the effect of Brexit’s political instability on our industry has been inescapable as Share XA new breed of pharma manufacturinghttps://pharmaphorum.com/r-d/views-analysis-r-d/a-new-breed-of-pharma-manufacturing/
The state of personalised medicine in 2019Things are good, and they’re getting better. When researchers completed mapping the human genome in 2003, it broke Share XThe state of personalised medicine in 2019https://pharmaphorum.com/views-analysis-oncology/the-state-of-personalised-medicine-in-2019/
Leveraging the FAIR principles of data in pharmaThe new FAIR guidelines aim to help pharma realise the full potential of data. As the amount of Share XLeveraging the FAIR principles of data in pharmahttps://pharmaphorum.com/views-analysis-digital/leveraging-the-fair-principles-of-data-in-pharma/
